EUCTR2012-001223-13-Outside-EU/EEA进行中（未招募）不适用
A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age. - Safety of Trivalent Subunit Influenza Vaccine administered to Healthy Children and adolescents.
ovartis Vaccines and Diagnostics0 个研究点目标入组 2,040 人开始时间: 2014年12月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,040
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •In order to participate in this study, all subjects met all of the inclusion criteria described.
- •1. Males and females =4 to =17 years of age at the time of enrollment.
- •2. Individuals' parents or legal guardians who have given written consent after the nature of the study has been explained according to local regulatory requirements (and where applicable according to local regulations, informed assent for subjects above the
- •specified age).
- •3. Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
- •4. Individuals and individuals’ parents or legal guardians who can comply with study procedures and were available for follow-up.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 2040
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •In order to participate in this study, all subjects met none of the exclusion criteria described.
- •1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study.
- •2. Individuals who took any analgesic/antipyretic medication within 24 hours of study vaccination.
- •3. Experienced a temperature =38.0°C or =100.4°F and/or any acute illness (defined as any moderate or severe symptom) within 3 days prior to day 1.
- •4. Individuals with any progressive or severe neurologic disorder, seizure disorder or recent history of Guillian-Barré syndrome (history of febrile convulsions was allowed).
- •5. Individuals/children's parents or legal guardians who were not able to comprehend and to follow all required study procedures for the whole period of the study.
- •6. Individuals with a history of illness or with an ongoing illness that, in the opinion of the investigator, may pose additional risk to the subject if he/she participates in the study.
- •7. Individuals with any serious chronic or progressive disease according to judgment of the investigator (including but not limited to insulin dependent diabetes, cardiac and renal or hepatic disease).
- •8. Individuals with known or suspected impairment of the immune system (including but not limited to HIV, autoimmune disorders (excluding stable Eczema and Hashimoto disease), immunosuppressive therapy, chronic use of systemic corticosteroids etc).
- •a. Stable eczema is defined as eczema involving less than 5% body surface, no significant morphological worsening and/or increase in medication in the previous 3 months.
- •b. Hashimoto disease is defined as an autoimmune disease attacking the thyroid gland and often resulting in hypothyroidism.
- •c. Chronic use of systemic corticosteroids is defined as use of systemic corticosteroids for more than 15 out of 30 days within the month prior to enrollment. The use of topic, inhaled and intranasal corticosteroids is not seen as systemic and therefore allowed.
- •9. Individuals who were pregnant or breastfeeding.
- •10. If =9 to =17 years female, of childbearing potential”, sexually active, and has not used any of the acceptable contraceptive methods” for at least 2 months prior to study entry:
- •a. Of childbearing potential is defined as status post onset of menarche and not meeting any of the following conditions: status after bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or status after hysterectomy.
- •b. Acceptable birth control methods are defined as one or more of the following:
- •- Sexual abstinence;
- •- Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical ring);
- •- Barrier (condom with spermicide or diaphragm with spermicide) each and every time during intercourse;
- •- Intrauterine device (IUD);
- •- Monogamous relationship with vasectomized partner. Partner must have been vasectomized for at least six months prior to the Subject’s study entry.
- •11. Female subjects of childbearing potential with a positive or indeterminate pregnancy test.
- •12. Any =9 to =17 year female of childbearing potential who was sexually active and refused to use an acceptable contraceptive method” through to the end of the study.
- •13. Individuals who were allergic to any of the vaccine components.
- •14. Individuals who have had ever a malignancy.
- •15. Individuals who have been diagnosed in the past 2 years wit
研究者
相似试验
进行中（未招募）
不适用
Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b.EUCTR2014-005159-24-Outside-EU/EEAovartis Vaccines and Diagnostics916
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineEUCTR2015-000728-27-EESeqirus UK Limited6,790
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineProfylaxis for Influenza virusMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-000728-27-PLSeqirus UK Limited10,692
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineProfylaxis for Influenza virusMedDRA version: 19.1 Level: PT Classification code 10022000 Term: Influenza System Organ Class: 10021881 - Infections and infestationsEUCTR2015-000728-27-BGSeqirus UK Limited6,790
进行中（未招募）
1 期
Clinical Study in Elderly to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to an Approved non-Flu VaccineProfylaxis for Influenza virusMedDRA version: 19.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2015-000728-27-LVSeqirus UK Limited10,692